Send in your spam and get the offenders listed
Create a rule in outlook or simply forward the spam you receive to firstname.lastname@example.org
The Small Biz Buzz
The Information Source for Regulated Domestic and International Small Pharmaceutical Business and Industry
FY 2016 User Fee Rates
1. FDA Announces Fiscal Year 2016 Generic Drug Fees
Today the U.S. Food and Drug Administration (FDA) published the fiscal year (FY) 2016 generic drug user fees as required under the Generic Drug User Fee Amendments of 2012 (GDUFA) in the Federal Register. This announcement includes the rates for the abbreviated new drug application (ANDA), prior approval supplement to an approved ANDA (PAS), Type II active pharmaceutical ingredient drug master file (DMF), generic drug active pharmaceutical ingredient (API) facilities, and finished dosage form (FDF) facilities user fees.
GDUFA authorizes FDA to assess and collect user fees for certain applications and supplements for human generic drug products, on FDF and API facilities, and on type II active pharmaceutical ingredient DMFs to be made available for reference.
These fees are effective on October 1, 2015, and will remain in effect through September 30, 2016.
2. Prescription Drug User Fee Rates for Fiscal Year 2016
FDA is announcing the rates for prescription drug user fees for FY 2016. The Federal Food, Drug, and Cosmetic Act (the FD&C Act), as amended by the Prescription Drug User Fee Amendments of 2012 (PDUFA V), authorizes FDA to collect user fees for certain applications for the review of human drug and biological products, on establishments where the products are made, and on such products. This notice establishes the fee rates for FY 2016.
3. Biosimilar User Fee Rates for Fiscal Year 2016
FDA is announcing the rates for biosimilar user fees for FY 2016. The FD&C Act, as amended by the Biosimilar User Fee Act of 2012 (BsUFA), authorizes FDA to assess and collect user fees for certain activities in connection with biosimilar biological product development, certain applications and supplements for approval of biosimilar biological products, establishments where approved biosimilar biological products are made, and a biosimilar biological product fee for each biosimilar biological product approved in a biosimilar biological product application.
4. Outsourcing Facility Fee Rates for Fiscal Year 2016
FDA is announcing the fiscal year FY 2016 rates for the establishment and reinspection fees related to human drug compounding outsourcing facilities (outsourcing facilities) that elect to register under the FD&C Act. The FD&C Act authorizes FDA to assess and collect an annual establishment fee from outsourcing facilities that have elected to register, as well as a reinspection fee for each reinspection of an outsourcing facility.
The Small Business and Industry Assistance program in the Center for Drug Evaluation and Research (CDER SBIA) provides guidance and information to regulated domestic and international small pharmaceutical business and industry through its website, email notifications, and workshops. This notification system provides current information from CDER/FDA via e-mail on a biweekly basis that is relevant to small pharmaceutical business, which includes Federal Register notices, guidances, workshop announcements, etc. This is an automated message delivery system. Replying to this message will not reach the CDER SBIA staff. If you have comments or questions, please contact us Monday through Friday 8:00AM - 4:30PM.
Please take our CDER SBIA survey: https://www.surveymonkey.com/s/CDERSBIA_Evaluation
All titles, content, publisher names, trademarks, artwork, and associated imagery are trademarks and/or copyright material of their respective owners. All rights reserved. The Spam Archive website contains material for general information purposes only. It has been written for the purpose of providing information and historical reference containing in the main instances of business or commercial spam.
Many of the messages in Spamdex's archive contain forged headers in one form or another. The fact that an email claims to have come from one email address or another does not mean it actually originated at that address! Please use spamdex responsibly.
Google + Spam © 2010- 2017 Spamdex - The Spam Archive for the internet. unsolicited electric messages (spam) archived for posterity. Link to us and help promote Spamdex as a means of forcing Spammers to re-think the amount of spam they send us.
Our inspiration is the "Internet Archive" USA. "Libraries exist to preserve society's cultural artefacts and to provide access to them. If libraries are to continue to foster education and scholarship in this era of digital technology, it's essential for them to extend those functions into the digital world." This is our library of unsolicited emails from around the world. See https://archive.org. Spamdex is in no way associated though. Supporters and members of http://spam.abuse.net Helping rid the internet of spam, one email at a time. Working with Inernet Aware to improve user knowlegde on keeping safe online. Many thanks to all our supporters including Vanilla Circus for providing SEO advice and other content syndication help | Link to us | Terms | Privacy | Cookies | Complaints | Copyright | Spam emails / ICO | Spam images | Sitemap | All hosting and cloud migration by Cloudworks.